截至2026年1月，先声药业集团共实现5项自研创新药早研项目对外技术授权许可，潜在交易总金额超46 亿美元。 1月27日，先声药业(02096.HK)与勃林格殷格翰宣布达成一项许可与合作协议，双方将共同开发先声药 业的临床前阶段TL1A/IL23p19双特异性抗体SIM0709，用于炎症性肠病的治疗。 根据协议，勃林格殷格翰获得该项目在大中华区以外的全球权益。先声药业可获得首付款，以及基于开 发、注册和商业里程碑的成功，最高可达10.58亿欧元的付款，此外还可获得大中华区以外净销售额提 成的特许权使用费。 ...

SIM0709为集团基于自有多特异性抗体平台自主研发的长效人源化双特异性抗体。SIM0709可同时靶向 肿瘤坏死因子配体超家族成员15(TL1A)和白介素-23(IL-23)，从而阻断参与炎症性肠病发生及进展的两 条核心通路。SIM0709在体外原代细胞实验和体内动物实验中均表现出优异的药效协同效果，甚至优于 两个单药的联用。 智通财经APP讯，先声药业(02096)发布公告，于2026年1月26日，集团附属公司先声药业有限公司(江苏 先声)与勃林格殷格翰签署独家授权许可协议。根据该协议条款，勃林格殷格翰将获得用于炎症性肠病 的TL1A/IL-23p19双特异性抗体SIM0709在大中华区以外的全球独家权益。本次授权许可进一步验证了 集团自身免疫研发平台的创新性及领先性。 根据该协议条款，集团有权收取4200万欧元的首付款，以及基于研发进展、监管审批及商业化等情况， 最高达10.16亿欧元的里程碑付款。此外，集团亦有权就大中华区以外的净销售额收取分级特许权使用 费。 （原标题：先声药业(02096)与勃林格殷格翰就SIM0709(TL1A/IL-23p19双特异性抗体)订立独家授权许 可协议） ...

Core Viewpoint - The announcement highlights a significant licensing agreement between the company and Boehringer Ingelheim for the dual-specific antibody SIM0709, indicating a strategic move to expand its market presence and revenue potential in the treatment of inflammatory bowel disease. Group 1: Licensing Agreement Details - The company’s subsidiary signed an exclusive licensing agreement with Boehringer Ingelheim on January 26, 2026 [1] - Boehringer Ingelheim will obtain global exclusive rights to SIM0709 outside of Greater China [1] - The agreement includes an upfront payment of €42 million, with potential milestone payments up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] Group 2: Financial Implications - The company is entitled to receive tiered royalties on net sales outside of Greater China [1] - The financial structure of the agreement suggests a strong revenue potential linked to the success of SIM0709 in the market [1]

Core Viewpoint - The announcement by Xiansheng Pharmaceutical (02096) regarding the exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709 highlights the company's innovative and leading position in the field of autoimmune research [1] Group 1: Licensing Agreement Details - Xiansheng Pharmaceutical's subsidiary, Jiangsu Xiansheng, signed an exclusive licensing agreement with Boehringer Ingelheim on January 26, 2026, granting Boehringer exclusive rights to SIM0709 outside Greater China [1] - The agreement includes an upfront payment of €42 million and potential milestone payments up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] - The company will also receive tiered royalties on net sales outside Greater China [1] Group 2: Product Information - SIM0709 is a long-acting humanized dual-specific antibody developed on the company's proprietary multi-specific antibody platform [1] - The antibody targets both TNF superfamily member 15 (TL1A) and interleukin-23 (IL-23), blocking two key pathways involved in the onset and progression of inflammatory bowel disease [1] - SIM0709 has demonstrated superior synergistic efficacy in both in vitro primary cell experiments and in vivo animal studies, outperforming the combination of two single agents [1]

根据该协议条款，集团有权收取4,200万欧元的首付款，以及基于研发进展、监管审批及商业化等情 况，最高达10.16亿欧元的里程碑付款。此外，集团亦有权就大中华区以外的净销售额收取分级特许权 使用费。 格隆汇1月27日丨先声药业(02096.HK)宣布，于2026年1月26日，集团附属公司先声药业有限公司("江苏 先声")与勃林格殷格翰签署独家授权许可协议。根据该协议条款，勃林格殷格翰将获得用于炎症性肠病 的TL1A/IL-23p19双特异性抗体SIM0709在大中华区以外的全球独家权益。本次授权许可进一步验证了 集团自身免疫研发平台的创新性及领先性。 ...

訂立獨家授權許可協議 本公告由先聲藥業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 （於香港註冊成立的有限公司） （股份代號：2096） 自願公告 與勃林格殷格翰就SIM0709 （TL1A/IL-23p19雙特異性抗體） 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年1月26日，本集團附屬公 司先聲藥業有限公司（「江蘇先聲」）與勃林格殷格翰簽署獨家授權許可協議（「該 協 議 」）。 根 據 該 協 議 條 款 ， 勃 林 格 殷 格 翰 將 獲 得 用 於 炎 症 性 腸 病 的 TL1A/IL-23p19雙特異性抗體SIM0709在大中華區以外的全球獨家權益。本次授權 許可進一步驗證了本集團自身免疫研發平臺的創新性及領先 ...

Summary of Key Points Core Viewpoint - On January 22, 35 Hong Kong-listed companies conducted share buybacks, totaling 17.519 million shares and an aggregate amount of HKD 3.81 billion [1]. Group 1: Company Buyback Details - Xiaomi Group-W repurchased 5.7138 million shares for HKD 201.73 million, with a highest price of HKD 35.240 and a lowest price of HKD 34.920, bringing its total buyback amount for the year to HKD 22.50 billion [1]. - Sunny Optical Technology repurchased 1.25 million shares for HKD 79.26 million, with a highest price of HKD 63.850 and a lowest price of HKD 62.450, totaling HKD 7.65 billion in buybacks for the year [1]. - Kuaishou-W repurchased 380,000 shares for HKD 29.97 million, with a highest price of HKD 79.150 and a lowest price of HKD 78.550, accumulating HKD 89.88 million in buybacks for the year [1]. Group 2: Buyback Amount Rankings - The highest buyback amount on January 22 was from Xiaomi Group-W at HKD 201.73 million, followed by Sunny Optical Technology at HKD 79.26 million, and Kuaishou-W among the top [1]. - In terms of buyback volume, Xiaomi Group-W led with 5.7138 million shares, followed by Sunny Optical Technology with 1.25 million shares and Guoquan with 1.198 million shares [1]. Group 3: Additional Company Buyback Information - China Resources Gas repurchased 947,600 shares for HKD 20.66 million, with a highest price of HKD 22.000 and a lowest price of HKD 21.560 [1]. - Xiansheng Pharmaceutical repurchased 862,000 shares for HKD 10.04 million, with a highest price of HKD 11.680 and a lowest price of HKD 11.570 [1]. - Geely Automobile repurchased 571,000 shares for HKD 9.49 million, with a highest price of HKD 16.740 and a lowest price of HKD 16.580 [1].

Group 1 - The company, Xiansheng Pharmaceutical (02096.HK), announced a share buyback on January 22, 2023, spending HKD 10.037 million to repurchase 862,000 shares [1]

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 先聲藥業集團有限公司 (於香港註冊成立之有限公司) 呈交日期： 2026年1月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02096 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 先声药业（02096）发布公告，于2026年1月20日斥资2221万港元回购188.4万股。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 先声药业（02096）发布公告，于2026年1月20日斥资2221万港元回购188.4万股。 责任编辑：卢昱君 责任编辑：卢昱君 ...